| Indication | For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes |
| Pharmacodynamics | Cefadroxil, a first-generation cephalosporin antibiotic, is used to treat urinary tract infections, skin and skin structure infections, pharyngitis, and tonsillitis. |
| Mechanism of action | Like all beta-lactam antibiotics, cefadroxil binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefadroxil interferes with an autolysin inhibitor. |
| Absorption | Cefadroxil is well absorbed on oral administration; food does not interfere with its absorption. |
| Volume of distribution | Not Available |
| Protein binding | Binding rates of cefadroxil were 28.1% by U.F. method |
| Metabolism | Not Available |
| Route of elimination | Over 90% of the drug is excreted unchanged in the urine within 24 hours. It crosses the placenta and appears in breast milk. |
| Half life | 1.5 hours |
| Clearance | Not Available |
| Toxicity | Nausea, vomiting, diarrhoea, allergic rashes may occur |